Delivery Order SPE2DB24D9131-SPE2DB24FXRP3
Award Date
7/22/24
Potential Completion Date
8/12/24
Potential Value
$1.5K
Federal Agency
Defense Logistics Agency
Awardee
DMS Pharmaceutical Group Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, was issued by the Defense Logistics Agency (DLA) under the Medical Supply Chain division. The $9,671.25 firm fixed-price delivery order is for the pharmaceutical product XOLAIR 150 MG/ML SYRINGEML, with a completion date of June 4, 2024. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the DLA to issue delivery...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, was issued by the Defense Logistics Agency (DLA) under the Medical Supply Chain division. The $13,539.75 firm fixed-price delivery order is for the supply of XOLAIR 150 MG/ML SYRINGEML, with a period of performance through September 17, 2024. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, was issued by the Defense Logistics Agency (DLA) on May 22, 2024. The $37,137.60 firm fixed-price delivery order is for the provision of 4564728307 XOLAIR 150 MG/ML SYRINGEML, a specialized pharmaceutical product. The contract has an ultimate completion date of June 13, 2024 and is not associated with any set-aside designation. DMS Pharmaceutical Group Inc. holds a significant...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, was issued by the Defense Logistics Agency (DLA) under the SPE2DB program. The $17,837.06 firm fixed-price delivery order is for the supply of XOLAIR 150 MG/ML SYRINGEML, a pharmaceutical product, with an ultimate completion date of September 7, 2021. DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, was issued by the Defense Logistics Agency (DLA) under the SPE2DB program. The $1,547.40 firm fixed-price delivery order is for the supply of XOLAIR 150 MG/ML SYRINGEML, a specialized pharmaceutical product, to support the recurring medical supply needs of military health facilities worldwide. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, was issued by the Defense Logistics Agency (DLA) under the SPE2DB program. The $4,642.20 firm fixed-price delivery order is for the provision of Xolair 150 mg/mL syringes, a specialized pharmaceutical product, with a period of performance through January 25, 2024. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA to supply a...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, was issued by the Defense Logistics Agency (DLA) under the SPE2DB program. The $93,062.40 firm fixed-price delivery order is for the supply of Xolair 150 mg/ml syringes, with an ultimate completion date of October 7, 2021. DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which runs...
This contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is a firm fixed-price delivery order with a ceiling value of $4,642.20. The award was issued by the Defense Logistics Agency (DLA) under the SPE2DB program, which is a single-award indefinite delivery contract (IDC) valued at up to $499,999,999 and running through December 31, 2025. This IDC allows the DLA to issue delivery orders for a comprehensive range of pharmaceutical items to...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $1,547.40 firm fixed-price delivery order is for the supply of Xolair 150 mg/ml syringes and has a total completion date of January 14, 2025. DMS Pharmaceutical Group holds a $499,999,999 single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue delivery orders for a...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a firm fixed-price delivery order under the Defense Logistics Agency's (DLA) SPE2DB program. The $8,510.70 contract is for the supply of XOLAIR 150 MG/ML SYRINGE, a specialized pharmaceutical product, with a completion date of January 25, 2023. DMS Pharmaceutical Group is a key supplier of a wide range of pharmaceutical items, including branded and generic drugs, biologics, and medical consumables,...